700 related articles for article (PubMed ID: 19576880)
1. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
[TBL] [Abstract][Full Text] [Related]
2. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.
Fodero-Tavoletti MT; Smith DP; McLean CA; Adlard PA; Barnham KJ; Foster LE; Leone L; Perez K; Cortés M; Culvenor JG; Li QX; Laughton KM; Rowe CC; Masters CL; Cappai R; Villemagne VL
J Neurosci; 2007 Sep; 27(39):10365-71. PubMed ID: 17898208
[TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein, Abeta and Alzheimer's disease.
Wirths O; Bayer TA
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):103-8. PubMed ID: 12551731
[TBL] [Abstract][Full Text] [Related]
4. Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies.
Obi K; Akiyama H; Kondo H; Shimomura Y; Hasegawa M; Iwatsubo T; Mizuno Y; Mochizuki H
Exp Neurol; 2008 Apr; 210(2):409-20. PubMed ID: 18164295
[TBL] [Abstract][Full Text] [Related]
5. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro.
Ono K; Noguchi-Shinohara M; Yoshita M; Naiki H; Yamada M
Exp Neurol; 2007 Feb; 203(2):579-83. PubMed ID: 17011551
[TBL] [Abstract][Full Text] [Related]
7. The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies.
Beyer K; Domingo-Sàbat M; Santos C; Tolosa E; Ferrer I; Ariza A
Brain; 2010 Dec; 133(Pt 12):3724-33. PubMed ID: 20959308
[TBL] [Abstract][Full Text] [Related]
8. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
Gallardo G; Schlüter OM; Südhof TC
Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
[TBL] [Abstract][Full Text] [Related]
9. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.
Kung MP; Hou C; Zhuang ZP; Skovronsky D; Kung HF
Brain Res; 2004 Oct; 1025(1-2):98-105. PubMed ID: 15464749
[TBL] [Abstract][Full Text] [Related]
10. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
[TBL] [Abstract][Full Text] [Related]
11. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.
Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M
Exp Neurol; 2009 Jun; 217(2):434-9. PubMed ID: 19289119
[TBL] [Abstract][Full Text] [Related]
12. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
[TBL] [Abstract][Full Text] [Related]
13. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain.
Ye L; Velasco A; Fraser G; Beach TG; Sue L; Osredkar T; Libri V; Spillantini MG; Goedert M; Lockhart A
J Neurochem; 2008 May; 105(4):1428-37. PubMed ID: 18221373
[TBL] [Abstract][Full Text] [Related]
14. Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects.
Aho L; Parkkinen L; Pirttila T; Alafuzoff I
Dement Geriatr Cogn Disord; 2008; 25(5):423-32. PubMed ID: 18391488
[TBL] [Abstract][Full Text] [Related]
15. alpha-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells.
Kazmierczak A; Strosznajder JB; Adamczyk A
Neurochem Int; 2008 Dec; 53(6-8):263-9. PubMed ID: 18804502
[TBL] [Abstract][Full Text] [Related]
16. Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene.
Yamaguchi K; Cochran EJ; Murrell JR; Polymeropoulos MH; Shannon KM; Crowther RA; Goedert M; Ghetti B
Acta Neuropathol; 2005 Sep; 110(3):298-305. PubMed ID: 15981014
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.
Klucken J; Ingelsson M; Shin Y; Irizarry MC; Hedley-Whyte ET; Frosch M; Growdon J; McLean P; Hyman BT
Acta Neuropathol; 2006 Feb; 111(2):101-8. PubMed ID: 16482476
[TBL] [Abstract][Full Text] [Related]
18. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies.
Deramecourt V; Bombois S; Maurage CA; Ghestem A; Drobecq H; Vanmechelen E; Lebert F; Pasquier F; Delacourte A
J Neuropathol Exp Neurol; 2006 Mar; 65(3):278-88. PubMed ID: 16651889
[TBL] [Abstract][Full Text] [Related]
19. 11C-labelled PIB analogues as potential tracer agents for in vivo imaging of amyloid beta in Alzheimer's disease.
Serdons K; Verduyckt T; Vanderghinste D; Borghgraef P; Cleynhens J; Van Leuven F; Kung H; Bormans G; Verbruggen A
Eur J Med Chem; 2009 Apr; 44(4):1415-26. PubMed ID: 18992967
[TBL] [Abstract][Full Text] [Related]
20. Characterization of fibrillation process of alpha-synuclein at the initial stage.
Tashiro M; Kojima M; Kihara H; Kasai K; Kamiyoshihara T; Uéda K; Shimotakahara S
Biochem Biophys Res Commun; 2008 May; 369(3):910-4. PubMed ID: 18329380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
